4-1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8+ T cells from melanoma sentinel lymph nodes

Copyright © 2010 Elsevier Inc. All rights reserved.

Détails bibliographiques
Publié dans:Clinical immunology (Orlando, Fla.). - 1999. - 137(2010), 2 vom: 02. Nov., Seite 221-33
Auteur principal: Sluijter, B J R (Auteur)
Autres auteurs: van den Hout, M F C M, Stam, A G M, Lougheed, S M, Suhoski, M M, van den Eertwegh, A J M, van den Tol, M P, van Leeuwen, P A M, Meijer, S, Scheper, R J, June, C H, de Gruijl, T D, Santegoets, S J A M
Format: Article en ligne
Langue:English
Publié: 2010
Accès à la collection:Clinical immunology (Orlando, Fla.)
Sujets:Journal Article 4-1BB Ligand Antibodies, Monoclonal Antigens, CD Epitopes, T-Lymphocyte Interleukins Lysosomal-Associated Membrane Protein 1 Melanoma-Specific Antigens Oligodeoxyribonucleotides ProMune plus... Receptors, IgG TNFRSF9 protein, human Tumor Necrosis Factor Receptor Superfamily, Member 9 Tumor Necrosis Factor-alpha Interferon-gamma 82115-62-6
Description
Résumé:Copyright © 2010 Elsevier Inc. All rights reserved.
We have been studying the re-activation of tumor-associated antigen (TAA)-specific CD8(+) T cells in sentinel lymph nodes (SLN) of melanoma patients upon intradermal administration of the CpG-B oligodeoxynucleotide PF-3512676. To facilitate functional testing of T cells from small SLN samples, high-efficiency polyclonal T cell expansion is required. In this study, SLN cells were expanded via classic methodologies with plate- or bead-bound anti-CD3/CD28 antibodies and with the K562/CD32/4-1BBL artificial APC system (K32/4-1BBL aAPC) and analyzed for responsiveness to common recall or TAA-derived peptides. K32/4-1BBL-expanded T cell populations contained significantly more effector/memory CD8(+) T cells. Moreover, recall and melanoma antigen-specific CD8(+) T cells were more frequently detected in K32/4-1BBL-expanded samples as compared with anti-CD3/CD28-expanded samples. We conclude that K32/4-1BBL aAPC are superior to anti-CD3/CD28 antibodies for the expansion of in vivo-primed specific CD8(+) T cells and that their use facilitates the sensitive monitoring of functional anti-tumor T cell immunity in SLN
Description:Date Completed 17.02.2011
Date Revised 15.12.2020
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2010.07.009